Laser-based Photoacoustic Tomography of Human Inflammatory Arthritis
|Arthritis, Rheumatoid||Procedure: Laser Based Photoacoustic Tomography, MRI, Ultrasound Procedure: laser based photoacoustic tomography, MRI, ultrasound|
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Laser-based Photoacoustic Tomography of Human Inflammatory Arthritis|
- Photoacoustic Imaging [ Time Frame: 2 weeks ]To determine if photoacoustic imaging (PAT) can accurately assist in the diagnosis of chronic rheumatoid arthritis
|Study Start Date:||February 2008|
|Estimated Study Completion Date:||January 2018|
|Estimated Primary Completion Date:||January 2018 (Final data collection date for primary outcome measure)|
Patients who have active disease affecting the joints in the hand will have Laser Based Photoacoustic Tomography (PAT), MRI, Ultrasound
Procedure: Laser Based Photoacoustic Tomography, MRI, Ultrasound
Healthy subjects will have scans on all finger joints of the hand with the scanning methods described above.
Healthy volunteers who do not have arthritis will also have Laser Based Photoacoustic Tomography (PAT), MRI, Ultrasound on the joints of their hand
Procedure: laser based photoacoustic tomography, MRI, ultrasound
Subjects with arthritis will have scans on all finger joints of the hand with the scanning methods described above.
The objective of this proposal is to adapt photoacoustic tomography (PAT), a novel, nonionizing, noninvasive, laser-based technology, for structural and functional imaging of human peripheral joints affected by inflammatory arthritis.
Combining the advantages of both light and ultrasound scanning, PAT holds promise to present objective optical information in subsurface joint tissues with high sensitivity and high spatial resolution.
This could be of considerable help in the early detection of inflammatory joint diseases. PAT may also prove useful in further understanding the pathophysiology of these disorders and assisting with therapeutic decisions, including assessment of new pharmacological therapies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00748254
|Contact: Xueding Wang, PhD||734 email@example.com|
|United States, Michigan|
|Universtity of Michigan Health System||Recruiting|
|Ann Arbor, Michigan, United States, 48109|
|Principal Investigator: Xueding Wang, PHD|
|Principal Investigator:||Xueding Wang, Ph.D||University of Michigan|